Levosimendán Kalceks

Levosimendan, the active ingredient in Levosimendán Kalceks, is a calcium sensitizer presented as an injectable solution for intravenous use. It is indicated for the management of acute decompensated heart failure and low cardiac output syndrome, providing hemodynamic support in hospitalized patients with severe cardiac dysfunction.

GNH USA supplies Levosimendán Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import and distribution across multiple regions.

Levosimendan is used in the management of heart failure syndromes where cardiac output is compromised. - Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Low cardiac output syndrome: enhances myocardial contractility and supports systemic perfusion. - Post‑cardiac surgery low output: facilitates hemodynamic stabilization after cardiac operations.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially during initial infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Tachycardia: increased heart rate. - Arrhythmias: occasional premature beats.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring intervention. - Myocardial ischemia: reduced coronary perfusion leading to chest pain. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Anaphylactic reaction: rare hypersensitivity requiring emergency care. - Hepatic enzyme elevation: abnormal liver function tests. - Thrombocytopenia: low platelet count in rare cases.

When using Levosimendán Kalceks, clinicians should observe several safety measures. - Monitor blood pressure: watch for hypotension, especially in patients receiving other vasodilators. - Assess cardiac rhythm: observe for arrhythmias during and after infusion. - Evaluate renal function: adjust use in severe renal impairment. - Review concomitant inotropes: avoid excessive catecholamine exposure. - Consider hepatic status: monitor liver enzymes if therapy is prolonged. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase levosimendan plasma levels. - Other calcium sensitizers: additive inotropic and vasodilatory effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - Diuretics: risk of electrolyte imbalance and volume depletion. - Additional inotropes (e.g., dobutamine): require hemodynamic monitoring. - Anticoagulants: monitor for bleeding if hypotension occurs. - Antihypertensives: adjust doses to avoid excessive blood pressure fall.